Fund newsNewsPortfolio News

Analysis demonstrates CeQur PAQ insulin delivery device is highly cost effective for people with Type 2 Diabetes not in glycemic control

CeQur Logo

CeQur® today announced that the Journal of Health Economics and Outcomes Research (JHEOR) published online an analysis evaluating the cost effectiveness of the company’s PAQ® Insulin Delivery Device. The analysis suggests that the simple three-day, wearable PAQ basal-bolus insulin delivery device is more cost-effective than multiple daily insulin injections (MDI) and results in a lifetime cost savings of more than $66,000 per person due to reduced insulin use and complications.

“Previous, published research has shown that PAQ can reduce barriers to insulin use and improve glycemic control,” said Jay Warner, Sr. VP of Commercialization at CeQur. “This analysis closes the loop by demonstrating that PAQ can help people with Type 2 diabetes achieve these clinical and disease management improvements while simultaneously reducing costs to the healthcare system.”

The paper published online in JHEOR describes results from a simulation model that used published equations to project long-term cost-effectiveness of continuous subcutaneous insulin infusion (CSII) as compared to MDI over 40 years, combined with data from the recent OpT2mise study. Cost-effectiveness was pre-defined using an industry accepted measure.*

Over a 40-year period, simulations showed that CSII was associated with a longer life expectancy (+0.32 years), longer event-free survival (+0.37 years), and longer quality adjusted life expectancy (+0.30 years) as compared to MDI. Individuals in the CSII group also were predicted to have considerable reduction in lifetime risk of developing diabetes-related complications as compared to the MDI group.

These improvements – and associated reductions in drug costs and the costs of treating diabetes complications – resulted in an estimated lifetime discounted savings of $66,883 for people with type 2 diabetes using CSII in place of MDI. In terms of cost-effectiveness, the analysis indicates that a simple insulin infusion device such as PAQ will be highly cost-effective at a price of around $13 per day and remain cost-effective up to a price of around $17 per day for people with type 2 diabetes. The analysis only included direct medical costs for the healthcare provider; researchers hypothesized that cost-effectiveness would increase if other types of health costs (such as indirect costs of premature mortality, costs for sick leave, etc.) were included.

“If simple insulin infusion devices such as PAQ provide a safe, effective and cost-effective treatment alternative to MDI, there is real potential for them to become a standard treatment alternative for selected type 2 diabetes populations,” said Jay Warner.